title: Rash induced by anti-tumor necrosis factor agents in an adolescent with Crohn's disease.
abstract: BACKGROUND
  A 17-year-old white male with Crohn's disease who was receiving maintenance infusions of the anti-tumor necrosis factor (TNF) agent, infliximab, presented with a new-onset psoriasiform skin rash. The rash was not responsive to topical or oral corticosteroids and worsened after infliximab infusions and after subsequent administration of a second anti-TNF drug, adalimumab.
  
  
  METHODS
  Full medical history and physical examination, including assessment of the morphology of rash and the temporal correlation with administration of anti-TNF agents.
  
  
  METHODS
  Anti-TNF-agent induced psoriasiform skin rash.
  
  
  RESULTS
  Discontinuation of anti-TNF therapy. The patient opted to have his gastrointestinal symptoms treated with oral mesalazine and metronidazole.
authors.affiliation: Division of Gastroenterology and Nutrition, Children's National Medical Center, 111 Michigan Avenue NW, West Wing 2.5, Suite 600, Washington DC 20010, USA.
authors.forename: Laurie S
authors.initials: LS
authors.lastname: Conklin
authors.forename: Bernard
authors.initials: B
authors.lastname: Cohen
authors.forename: Lindsay
authors.initials: L
authors.lastname: Wilson
authors.forename: Carmen
authors.initials: C
authors.lastname: Cuffari
authors.forename: Maria
authors.initials: M
authors.lastname: Oliva-Hemker
mesh_terms: D000068879:Adalimumab; D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001707:Biopsy, Needle; D003424:Crohn Disease / Q000175:diagnosis / Q000188:drug therapy*; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D005076:Exanthema / Q000139:chemically induced / Q000473:pathology; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D000069285:Infliximab; D007262:Infusions, Intravenous; D008297:Male; D018570:Risk Assessment; D014409:Tumor Necrosis Factor-alpha / Q000009:adverse effects* / Q000037:antagonists & inhibitors*; D028761:Withholding Treatment
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab